Therapeutic Spotlights
In-depth analysis of enrollment trends, site capabilities, and development pipeline dynamics across our core therapeutic areas.
Current Spotlights
Each spotlight provides a detailed view of the therapeutic landscape, including enrollment dynamics, site requirements, and emerging trends shaping trial design and execution.
Solid Tumors & Immuno-Oncology
Oncology remains the largest segment of our network portfolio, with 42 active studies spanning non-small cell lung cancer, breast cancer, colorectal cancer, and melanoma. Immuno-oncology combinations and biomarker-driven trials represent the fastest-growing subsegment.
Alzheimer's, Parkinson's & Migraine
CNS trials present unique enrollment challenges due to diagnostic complexity, caregiver involvement requirements, and high screen failure rates. Our network has developed specialized capabilities in cognitive assessment training, caregiver engagement protocols, and long-term retention strategies.
Rheumatoid Arthritis, Lupus & IBD
Immunology studies benefit from relatively large patient populations and well-established referral networks, but face increasing competition for eligible patients as the number of active studies grows. Sites with strong rheumatology and gastroenterology practices consistently outperform.
Heart Failure, Arrhythmia & Cardiometabolic
Cardiovascular trials represent our second-largest therapeutic portfolio with 28 active studies spanning heart failure, atrial fibrillation, hypertension, and lipid-lowering indications. SGLT2 inhibitor crossover from diabetes and inflammation-targeted therapies are reshaping the pipeline.
Gene Therapy, Enzyme Replacement & Genetic Conditions
Rare disease trials require national and international recruitment strategies for ultra-small patient populations. Our network supports 14 active studies across gene therapy, enzyme replacement, and substrate reduction programs with deep patient advocacy partnerships.
Diabetes, Thyroid & Metabolic Bone
Endocrinology studies benefit from large patient populations, particularly in type 2 diabetes, with 22 active studies across our network. GLP-1 receptor agonist success has created unprecedented pipeline expansion, while CGM integration is transforming endpoint measurement.
Atopic Dermatitis, Psoriasis & Inflammatory Skin Disease
Dermatology trials are growing rapidly with 18 active studies driven by JAK inhibitors and IL-targeted biologics across atopic dermatitis, psoriasis, alopecia areata, and hidradenitis suppurativa. Validated scoring systems and photographic endpoints require specialized infrastructure.
NASH/MASH, Liver Disease & Functional GI Disorders
Gastroenterology studies span 16 active protocols with MASH therapeutics dominating trial volume. Non-invasive biomarkers are increasingly replacing liver biopsy requirements, while functional GI disorder programs address IBS, GERD, and celiac disease.
Antivirals, Antimicrobial Resistance & Vaccines
Infectious disease programs encompass 12 active studies across antivirals, novel antibiotics, and next-generation vaccines. AMR-targeted agents and long-acting HIV prevention represent high-growth areas, while mRNA vaccine platforms are expanding into new pathogens.
Asthma, COPD & Interstitial Lung Disease
Pulmonology trials span 20 active studies across severe asthma biologics, COPD exacerbation reduction, and IPF anti-fibrotic programs. Spirometry standardization and eosinophil-driven stratification remain central to enrollment planning and site qualification.
Retinal Disease, Glaucoma & Ocular Gene Therapy
Ophthalmology trials encompass 10 active studies across wet and dry AMD, DME, glaucoma, and inherited retinal diseases. Extended-durability anti-VEGF formulations and geographic atrophy programs represent the largest growth areas, while ocular gene therapy demands specialized surgical infrastructure.
Hemoglobinopathies, Coagulation Disorders & Hematologic Malignancies
Hematology trials span 16 active studies across sickle cell disease, hemophilia, ITP, and hematologic malignancies including lymphoma, leukemia, and myeloma. Gene therapy for hemoglobinopathies and bispecific T-cell engagers for blood cancers represent transformative pipeline advances.
CKD, Glomerular Disease & Renal Innovation
Nephrology trials encompass 10 active studies across CKD, IgA nephropathy, diabetic kidney disease, and FSGS. SGLT2 inhibitors have transformed the CKD treatment landscape, while eGFR slope as a surrogate endpoint is accelerating development timelines.
Osteoarthritis, Gout & Connective Tissue Disease
Rheumatology trials span 14 active studies focused on osteoarthritis disease modification, gout management, spondyloarthritis, vasculitis, and systemic sclerosis. OA disease-modifying therapies represent the largest unmet need, while rare autoimmune conditions are gaining pipeline attention.
GLP-1 Therapies, Weight Management & Metabolic Syndrome
Metabolic and obesity trials represent our fastest-growing therapeutic area with 24 active studies. The transformative success of GLP-1 agonists has created unprecedented pipeline expansion into dual and triple agonists, while cardiometabolic outcome requirements are extending study durations.
Discuss Your Therapeutic Area
Connect with our team to explore site capabilities and enrollment strategies specific to your therapeutic focus.